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The activity of β-lactamases is easy to estimate, they often exhibit very high turn-
over numbers and many of them are quite stable. For these reasons they have emerged as 
promising reporter enzymes to study gene expression and as models to analyse protein-
ligand interactions. They also accept the insertion of rather large peptides without losing 
their activity. This has allowed the development of practically useful technologies which 





β-lactamases have been extensively used as biochemical markers for identification of β-
lactam antibiotics which are active against bacterial pathogens. But during the last decade, 
class A β-lactamases have emerged as promising reporter enzymes to study gene expression 
and to study protein/ligand interactions. In this context these enzymes are very attractive 
because they are monomeric, very stable and of small size [1]. Their three-dimensional 
structures are well-defined and they are considered as very efficient enzymes [2]. Among the 
various reporter enzymes described in the literature, β-lactamases are particularly interesting 
because they are not expected to interfere with the function of most of the proteins to which 
they might be fused and the absence of endogenous counterparts in mammalian cells [3]. 
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They have also been successfully expressed in prokaryotic and eukaryotic cells allowing their 
utilizations for in vitro as well as in vivo applications [4]. They can be overexpressed with 
prokaryotic expression systems so that their production times and costs are drastically 
reduced [5]. Their success is also partly due to the development of a variety of β-lactam 
substrates including chromogenic β-lactams for immunoassays, fluorescent membrane-
permeant β-lactams which allow cell imagery, flow cytometry and gene expression assay, and 
non-toxic β-lactam prodrugs for antibody-directed enzyme prodrug therapy [3, 6-8].  
Thanks to this uniqueness they have been extensively employed as “reporters” or 
“sensors” for monitoring various biological processes and interactions. Sensitive and rapid 
detection of β-lactamase activity in biological samples is thus of importance in both research 




1. β-LACTAMASES AS REPORTERS OF GENE EXPRESSION 
 
Biological specificity is mediated by the precise and selective regulation of gene 
expression in response to intrinsic developmental programs and extrinsic signals. To 
understand the regulation of gene expression, it is essential to use an assay of high sensitivity 
and fidelity that reports expression at the level of a single cell [9]. Correlation of gene 
expression with physiological responses and developmental fates would be facilitated by non-
destructive transcriptional assays compatible with high-throughput methods such as 
fluorescence-activated cell sorting (FACS). Such assays are currently based on reporter genes 
such as those of chloramphenicol acetyltransferase, secreted alkaline phosphatase, β-
galactosidase, and firefly luciferase [10] which typically require cell permeabilization or lack 
single-cell resolution, whereas the green fluorescent protein (GFP) is a relatively insensitive 
reporter due to the lack of enzymatic amplification [9, 11]. In this context, Zlokarnik and 
coworkers demonstrated the use of the 29 kDa isoform of the TEM-1 β-lactamase and a 
membrane-permeant, fluorogenic ester substrate to measure gene expression in single live 
mammalian cells with high sensitivity and real-time responses. To limit interference from 
variations in cell size, probe concentration, excitation intensity, and emission sensitivity, they 
constructed a new substrate molecule presented in figure 1 based on the following strategy: 
since cleavage of cephalosporins by a β-lactamase triggers the spontaneous elimination of any 
leaving group in the C3’ position [9], they attached two fluorophores with overlapping spectra 
on the 7’ and 3’ positions of a cephalosporin. When on the same molecule, these exhibit 
efficient fluorescence energy transfer (FRET). The β-lactamase action allows the release of 
the C3’ fluorophore, disrupting FRET and reestablishing fluorescence emission from the 7’ 
donor. For that purpose they used a membrane-permeant ester derivative of a cephalosporin 
CCF2/AM. The donor fluorophore was 7-hydroxycoumarin and the 3’-acceptor fluorophore 
was fluorescein. They validated this substrate with several receptor-regulated gene 
expressions under the control of adequate promoters in living mammalian cells by visualizing 
the β-lactamase-catalysed hydrolysis of CCF2/AM. This was done in both transitory 
expression systems and also in stable cell lines.  
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Figure 1. Schematic representation of the CCF2/4-AM substrate molecule loading into cultured cells 
[12]. The esterified (acetoxymethylated: AM) form of the CCF2/4 substrate, called CCF2/4-AM, 
diffuses across the cell plasma membrane where endogenous esterases convert it to CCF2/4, thereby 
trapping it inside the cell. Exciting CCF2/4 at 408 nm leads to efficient FRET from the coumarin 
moiety to the fluorescein derivative and produces green fluorescence detectable at 530 nm. After 
CCF2/4 hydrolysis by the β-lactamase, the two fluorophores separate causing loss of FRET. Excitation 
at 408 nm now results in blue fluorescence detectable at 460 nm.  
 
Figure 2. Sites of pentapeptides insertions in the three-dimensional structure of TEM-1 β-lactamase 
[25]. Numbers identify the insertion positions. Green, cyan and red residues indicate pentapeptide 
insertions which result in high-level, intermediate-level and loss of ampicillin hydrolysis activity, 
respectively. 
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β-Lactamase reporter gene assays have also been successfully used as readouts for 
ligand-induced activation of G protein-coupled receptors [13], for selecting high-producing 
clones in the yeast Pichia pastoris [14], to identify inhibitors of the hepatitis C virus (HCV) 
replication [15], and to monitor spatially restricted patterns of genes expression in the early 
zebrafish embryos [16].  
 
 
1. β-LACTAMASE AS A REPORTER ACTIVITY  
 
The β-lactamase reporter activity has also been extensively used to study biochemical 
processes, especially protein/ligand interactions. For this purpose, three different possibilities 
detailed in this section were developed.  
 
 
The Use of β-lactamase Fusion Proteins 
 
An interesting application of β-lactamase fusion proteins is the use of this reporter system 
to study exported proteins. For example McCann and coworkers identified proteins exported 
by Mycobacterium tuberculosis growing in host cells with the assumption that, when used in 
protein fusions, a β-lactamase can report on the subcellular location of another protein as 
measured by the protection from β-lactam antibiotics afforded to a mutant strain of 
M.tuberculosis lacking its major β-lactamase [17]. The exported proteins of M.tuberculosis 
have received attention for a long time because of the well-established fact that the majority 
of bacterial virulence factors and antigens are proteins exported to the bacterial cell wall or 
secreted [18]. Proteomic and genetic methods were used to identify proteins exported from 
the cytoplasm especially enzymatic reporter systems [19-21]. Among these reporter systems, 
β-lactamases are exported proteins that were not initially employed in M.tuberculosis because 
of endogenous β-lactam resistance. But the construction of a β-lactam-sensitive mutant of this 
bacterium has opened the door to the utilization of β-lactamases as reporters of protein export 
directly in M.tuberculosis with the β-lactam-resistance as a powerful indicator of export. This 
reporter enzyme presents the advantage of using a selection system instead of a more labor-
intensive screening process. This study demonstrated that the TEM-1 β-lactamase lacking its 
export signal sequence conferred β-lactam resistance when fused to the major M.tuberculosis 
endogenous signal sequences. They further showed that β-lactamase fusion proteins report on 
protein export even while the bacterium is growing in its host cell namely human 
macrophages.  
In another interesting study, Simonen and coworkers [22] investigated the relationship 
between folding and secretion competence of a Saccharomyces cerevisiae secretory protein: 
hsp150. They fused the E.coli TEM-1 β-lactamase, deprived of its own signal sequence, to 
the C-termini of various portions of hsp150. The evaluation of the β-lactamase activity of the 
different chimeric proteins was used to study the effect of the hsp150-carrier sequence on the 
folding of the β-lactamase portion and the effect of folding on the secretion competence of 
the fusion proteins. With this reporter system they identified the hsp150 subunits responsible 
for both the folding and the secretion of the fused protein.  
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The TEM β-lactamse was also used to probe the topology of membrane proteins [23]. 
When the β-lactamase gene (devoid of signal peptide) is fused to DNA fragments encoding 
portions of increasing lengths of the target protein, starting from the N-terminus, the β-
lactamase can localise into the periplasm or the cytoplasm. Resistance of single-cell colonies 
to ampicillin is increased in the first case, not in the second. This technique was used to 
elucidate the transmembrane organisation of the Bacillus licheniformis BlaR sensory 
transducer (see chapter 17) involved in the induction of β-lactamase in this bacterium [24]. 
 
 
The Use of β-lactamases as Carrier Proteins 
 
Besides the use of β-lactamases as fusion proteins, protein and or peptide insertions were 
also demonstrated to be efficient tools especially to study protein/ligand interactions. Indeed, 
class A β-lactamases were demonstrated to accept insertions of both random peptides as well 
as structured protein/domain. Hallet and coworkers determined the tolerance of the E.coli 
TEM-1 β-lactamase to 23 randomly inserted pentapeptides (Figure 2). They associated the 
phenotypes of the mutated β-lactamases to the local peptide structures in which the 
pentapeptide insertions occurred and to their positions in the three-dimensional structure of 
the enzyme [25]. 
In the case of complete domains or proteins, the location of the insertion site was 
demonstrated to strongly influence the tolerance of the inserted polypeptide. For example 
Betton and coworkers inserted the TEM-1 β-lactamase into the maltose-binding protein 
MalE. This resulted in a chimeric protein retaining the activity of both parental proteins [26]. 
They showed that this bifunctionality was dependent on the insertion site and that the activity 
of one of the chimeric protein partners could be modulated by an independent ligand specific 
for the other partner of the macromolecule. Similarly, Collinet and coworkers inserted TEM-1 
into four surface loops of the phosphoglycerate kinase (PGK) and showed that the chosen 
insertion site strongly influenced the tolerance to insertions [27] (Figure 3).  
The class A BlaP β-lactamase produced by Bacillus licheniformis was used as a carrier 
protein to study the function of heterologous protein fragments [28]. The chitin-binding 
domain (ChBD) of the human macrophage chitotriosidase was inserted into a solvent exposed 
loop of BlaP far away from its active site (position 198) (Figure 4). The product of this 
construction behaved as a soluble chimeric protein that conserved both the capacity to bind 
chitin and to hydrolyze β-lactams. Using the β-lactamase reporter activity, the relative 
association constant (Kr) between the chimeric protein and insoluble chitin was determined. 
Furthermore, this hybrid protein allowed the detection of chitin in fungal cell wall and to 
measure the amount of protein bound to various insoluble polysaccharides with a good 
accuracy. This is a major advantage of this system when compared to the techniques already 
described in the literature attempting to determine the affinity parameters of carbohydrate 
binding domains. Indeed, in these studies, protein concentration determination assays or 
intrinsic fluorescence measurements used to characterize the interaction between the protein 
domains and the insoluble polysaccharides resulted in large standard deviations [29-30]. 
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Figure 3. A. Structure of the yeast PGK. The four tested insertion sites are indicated. B. Illustrative 
scheme of the chimeric protein in which the E.coli TEM-1 β-lactamase was inserted into the yeast PGK 
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The Use of β-lactamase Fragments Complementation  
 
The complementation of β-lactamase fragments fused to interacting polypeptides that 
regenerate enzymatic activity was also used as a reporter system in assays monitoring 
inducible protein-protein interactions in eukaryotic cells (Figure 5) [4, 12, 31]. This strategy, 
called protein fragment complementation assay (PCA), is based on protein interaction assisted 
folding of rationally designed fragments of enzymes. It has also been used with other reporter 
proteins such as luciferase, β-galactosidase, the green fluorescent protein and the 
dihydrofolate reductase. However the advantage of the β-lactamase activity is that no 
ortholog exists in eukaryotes, and thus PCA based on β-lactamase activity can be used 
universally in eukaryotic cells and many prokaryotes with no intrinsic background activity. β-
lactamase also has the desirable features of enzymatic amplification and facile in vivo and in 
vitro assays. Finally as mentioned above, it has the advantage that the versatile membrane-
permeable fluorescent β-lactamase substrate, CCF2/AM, is available which allows 
ratiometric fluorescence detection and thus superior reproducibility and excellent 
quantification of the results in intact cells [9]. β-lactamase complementation also exhibits an 
extremely high signal-to noise ratio [31].  
The strategy for the selection and design of fragments in the E.coli TEM-1 β-lactamase 
was based on the analysis of its structure and consists in the cleavage of the enzyme between 
Glu 197 and Leu198, because this site is located on a surface loop opposite to the active site 
(Figure 6) and produces fragments of similar lengths. It contains no periodic secondary 
structure, and the fragments can fold independently into native-like structures [4]. This β-
lactamase complementation assay has been validated with several known protein-protein 
interactions, including the homodimerizing GCN4 parallel coiled-coil leucine zipper, the 
heterodimerizing soluble Bad and truncated (Bcl2T) pair [4] and even the interaction between 
a transmembrane receptor and cytoplasmic protein as in the case of the epidermal growth 
factor receptor and the FKBP12 cytoplasmic protein [31]. 
 
 
Figure 4. Ribbon diagram of the three dimensional structure of the Bacillus licheniformis BlaP β-
lactamase. α-helices and β-sheets are represented in blue and orange respectively. The insertion site is 
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indicated by an arrow. It is located in a loop connecting helix 9 to helix 10 between residues Lys 197 
and Leu 198. Residues involved in the enzymatic catalysis are shown in red.  
 
Figure 5. Schematic representation of the ß-lactamase based protein fragment complementation assay 
(PCA) [32]. The β-lactamase is split into two inactive fragments of similar lengths. Interacting fusion 
proteins attached to the fragments allow fragment reassembly, which can be detected by growing cells 
on media containing ampicillin or alternatively by using a chromogenic substrate.  
 
Figure 6. Representation of the E.coli TEM-1 β-lactamase with the N- and C- terminal subfragments 
highlighted in red and blue respectively [33]. An example of two co-expressed constructs whose 
+	  Amp
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complementation is monitored in the PCA system is also represented: the TNF-α target (yellow) is 
fused to the N-terminal fragment and an affibody protein library member (orange) to the C-terminal 
fragment.  
 
Figure 7. Schematic representation of the 2-step protocol used to prepare purified ChBD. Purified 
ChBD is collected in the flow through after loading the digested chimeric protein on the HisTrap™ 
chelating HP [37].  
More recently, Löfdah and coworkers applied this TEM-1 β-lactamase based PCA 
system to select affibody molecules binding the human tumor necrosis factor-α (TNF-α) from 
a combinatorial library [33]. This system has also been used for the high throughput screening 
of toll-like receptor signaling inhibitors [34]. 
 
 
3. β-LACTAMASE AS AN ALTERNATIVE FOR THE PRODUCTION  
OF DIFFICULT TO EXPRESS PROTEIN DOMAINS 
 
Many Escherichia coli expression vectors are available to produce and to purify proteins 
fused to affinity tags, such as the Schistosoma japonicum glutathione S-transferase (GST), the 
E.coli maltose binding protein and thioredoxin [35-36]. All these systems allow the 
subsequent proteolytic cleavage of the fusion protein to separate the protein of interest from 
the affinity tags. But a common feature of these systems is the limited utility of the affinity 
tag in the biochemical characterization of the studied protein. Recently, Vandevenne and 
coworkers [37] described a system able to elicit the expression of protein fragments inserted 
into a solvent exposed loop of the Bacillus licheniformis BlaP class A β-lactamase. Two 
thrombine (thb) cleavage sites were engineered on both sides of the β-lactamase permissive 
loop in order to cleave off the exogenous protein fragment from the carrier protein by an 
original two-step procedure [37]. This system has been used to express the chitin binding 
domain of the human macrophage chitotriosidase (ChBD) inserted between the two protease 
cleavage sites. This 73 residues polypeptide contains 3 disulfide bridges reported as essential 
to its chitin binding activity [38-39]. Recent studies showed that ChBD expression in E.coli 
can be achieved by fusing the domain to the glutathion-S-transferase (GST) [39] but with 
very limited yields which, combined with its low solubility and stability, strongly limited the 
characterization of ChBD. Upon insertion into the carrier β-lactamase, the resulting chimeric 
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  /CHBD/	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protein named BlaP Thb/ChBD/Thb was successfully produced in E.coli in a soluble form 
with a very good yield (≈ 20 mg of pure protein per liter of culture) and purified to 
homogeneity. The separation of ChBD from its carrier protein did alter neither the 
biochemical activity nor the native disulphide bridge formation of the inserted ChBD. Pure 
ChBD poplypeptides were prepared based on both the mutual affinity of the N- and C-
terminal fragments of BlaP after thrombin cleavage and the presence of a poly-histidine tag at 
the C-terminal end of BlaP. The two-step purification procedure presented in figure 7 consists 
in a cleavage of BlaP Thb/ChBD/Thb with thrombin in solution followed by the elimination 
of BlaP fragments on a HisTrap Chelating HP column. This step can be repeated until the 
desired level of purity is obtained. This is a good example of the utilization of the β-lactamase 
carrier protein to increase the production and the solubility of difficult to express protein 
fragments and facilitate their purifications and studies.  
 
 
4. β-LACTAMASE AS A BIOSENSING MOLECULE 
 
Biosensors are based on induced conformational changes of proteins to detect small 
ligands and ions [40]. The proteins selected for biosensor construction are usually allosteric 
enzymes which upon ligand binding exhibit altered catalytic efficiencies. Some hydrolytic 
enzymes have been widely used [41-42]. However, despite all the advantages exhibited by β-
lactamases, the rational design of biosensors based on these enzymes remains a great 
challenge since neither substrate binding nor catalysis has been reported to induce large 
conformational changes in these proteins. The Ω-loop, a loosely packed 17-residue segment 
(residues 163-179) adjacent to the active site of class A β-lactamases, appears to be flexible 
and its motion essential to the enzymatic reaction [43]. This Ω-loop contains a key active-site 
residue Glu-166, whose substitution impairs but still allows acylation of the enzyme by β-
lactam antibiotics. By contrast, the deacylation step is much more affected [44]. Moreover, 
crystal structures of the enzyme show that the Glu-166 side chain is pointing toward the 
active site. Based on these results Chan and coworkers hypothesized that, if an environment-
sensitive fluorescent probe is placed specifically at the 166 position, an enzyme with 
drastically suppressed hydrolytic activity that can function as a biosensor can be constructed. 
To demonstrate this concept, they constructed a mutant of the β-lactamase I from Bacillus 
cereus 569/H, E166C, in which the Glu-166 residue on the Ω-loop was replaced by a cysteine 
residue. The E166C mutant exhibiting a 1800-fold lowered efficiency was labeled with the 
thiol-specific fluorophore (fluorescein-5-maleimide) to give the labeled E166Cf mutant. As 
the wild-type β-lactamase I contains no cysteine residue, this single-point mutation allows the 
specific attachment of a thiol-reactive fluorophore. In aqueous buffers, E166Cf is only weakly 
fluorescent but when β-lactam antibiotics are added, the fluorescence intensity at 515 nm 
increases as a function of the antibiotic concentration (Figure 8). The increase in fluorescence 
intensity can be observed even when the antibiotic concentration is as low as 0.05 µM, 
indicating that an extremely sensitive biosensor for β-lactam antibiotics has been obtained 
[45]. Indeed the detection of antibiotics present at trace levels in food (e.g. milk) is an 
important application since the ubiquitous presence of antibiotics can have serious health and 
economical consequences ranging from allergic reactions and the evolution of antibiotic-
resistant bacteria [41] to serious problems in the dairy industry.  




Figure 8. (A) Molecular models of the fluorescein label (green) on E166Cf before and (B) after binding 
with penicillin G (red). (C) Fluorescence spectra of E166Cf in the presence of penicillin G. Red, green, 
light blue, and black, after addition of 0.1, 1.0, 10, 100 µM antibiotics respectively [41]. 
In another interesting work, Legendre and coworkers attempted to induce conformational 
changes in β-lactamases to study protein interactions [46]. Their strategy was to chemically 
modify the TEM-1 β-lactamase by coupling of a hapten molecule in order to create a 
conjugate whose activity is regulated by the binding of an antihapten antibody. Peptide 
mimotopes were chosen as haptens. They are nonlinear protein epitopes selected from phage 
display libraries [47]. These peptides bind to antibodies or to other proteins with high affinity. 
This technology was used to insert random peptides libraries near the active site of TEM-1 
displayed on the phage fd in fusion to the coat protein pIII and to select variants in which the 
engineered mimotopes serve as binding sites for antibodies directed against antigens of 
interest. Combination of both elements (insertion of degenerate sequences and in vivo 
selection of active clones) permitted the production of enzyme libraries in which a large 
variety of antigen epitopes or mimotopes were perfectly integrated within the protein 








Marylène Vandevenne, Moreno Galleni and Patrice Filée 12 
 
5. THE USE OF β-LACTAMASES IN IMMUNOASSAYS 
 
Utilization of enzyme immunoassays (EIAs) is widespread for the detection and/or 
quantification of small organic analytes (e.g. drugs, hormones) [46] or for the recognition of 
microbial antigens in clinical specimens. EIA systems utilize enzyme-catalysed reactions to 
measure the binding of antigens to specific antibodies [48-49]. The performance 
characteristics of EIAs are thus determined to a great extent by the reaction kinetics of the 
enzyme-substrate system used as the indicator [50]. Enzymes which are usually used in these 
assays include alkaline phosphatise [51], horseradish peroxidase [52], and β-galactosidase 
[53]. These enzymes have been chosen because they can be linked to immunoglobulin 
molecules to yield stable antibody-enzyme conjugates which retain a substantial portion of 
the enzymatic and antigen-binding activities of the original reagents [54]. β-lactamases 
represent another group of enzymes useful for EIA systems and present several advantages. 
They are easily available and exhibit favourable reaction kinetics with a wide range of 
available substrates devoid of mutagenic or carcinogenic potential [55-56]. In addition, β-
lactamases can be linked to biotin, thus allowing their use in avidin-biotin systems [48, 57-
58]. A few examples in which β-lactamases have been successfully implemented into EIAs 
are described.  
β-lactamase enzyme-linked immunosorbent assays (ELISA) for various reproductive 
hormones have been developed and were found to be quite useful in fertility related problems. 
This system has now replaced radioimmunoassay (RIAs) which use radioactive labels. The 
short half-life of I125-labeled hormones and the potential of health hazards in handling and 
disposing of gamma ray emitters limit the useful lifetime of a kit and increase its cost, thereby 
hindering its general application [59]. In this context, Shrivastav and co-workers used β-
lactamase EIAs to detect prolactin in plasma at concentrations as low as 2,5 ng/ml [60]. This 
assay has been used to detect and estimate a wide range of β-lactamase labelled hormones 
and steroids in plasma such as testosterone derivatives [61-62], cortisol [59], human chorionic 
gonadotropin [63], estradiol, lutropin, follitropin [60] with a high sensitivity and a high 
specificity. Furthermore a prototype of a ready-to-use β-lactamase based ELISA kit has been 
developed by Khatkhatay and co-workers [64].  
As mentioned above, the noncovalent but exceptionally strong avidin-biotin interaction 
has been implemented in β-lactamase based immunoassays. In such an indirect procedure, 
biotin labelled antibodies were used [49] to quantify and specifically detect antigens of the 
human adenoviruses and the rotavirus [54]. 
 
 
Figure 9. Schematic representation of a β-lactam antibiotic hydrolysis by a β-lactamase accompanied 
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Other interesting β-lactamase-based immunoassays are those implementing the biosensor 
technology. The enzyme-based biosensors technology relies on two operational mechanisms. 
The first one involves the catalytic transformation of a non-detectable molecule into a 
detectable form. The second mechanism involves the detection of molecules that modulate 
the enzyme activity. Among the various detection methods, the potentiometric measurements 
rely on the development of charges related to the reporter enzyme activity. Most 
potentiometric biosensors for detection of environmental analytes have used enzymes that 
catalyze the appearance or disappearance of protons. For instance, phosphoric and carbamic 
pesticides can be evaluated through the use of a pH electrode that measures the activity of 
acetylcholinesterase [65-66]. In this approach, polyalanine (PANI) is an efficient polymer for 
developing biosensors because its redox potential, conductivity and adsorption wavelength 
are modified in response to a pH variation [67-69]. In this context, since the hydrolysis of β-
lactams generates protons, β-lactamases are good candidates for the development of enzyme-
based biosensors (Figure 9).  
A good example of application of these biosensors has been described by Sergeyeva and 
coworkers in which a β-lactamase label-based potentiometric biosensor for the detection of 
α-2 interferon was used consisting of a highly specific, stable and miniature electrochemical 
biosensor based on pH-sensitive field effect transistors (pH-FET) [70]. A specific sensing 
element was built by immobilizing α-2 interferon on the gate of a pH-FET. The interaction 
between anti-interferon antibodies labeled β-lactamase and interferon-pH-FET (in the 
presence of a specific enzyme substrate) leads to a local pH-change at the surface of the 
transducer and produces an electrochemical signal which is proportional to the conjugate 
concentration.  
Gaudin and coworkers also used a similar β-lactamase-based biosensor immunoassay for 
the screening of penicillins residues in milk [71]. 
 
 
6. IMPLEMENTATION OF β-LACTAMASES 
 INTO THE PHAGE DISPLAY TECHNOLOGY 
 
Phage display is a powerful technology to study protein/ligand interactions. In this 
technique, peptides, proteins or protein fragments are expressed on the surface of phage 
particles in fusion with one of their coat proteins [72]. The advantage of this system rests on 
the physical link between the heterologous polypeptide expressed at the surface of the phage 
and the corresponding nucleotide sequence cloned into the phagemid genome. The ability of 
each phage to individually replicate and to display a specific polypeptide on its surface allows 
a high throughput screening of libraries of variant nucleotide sequences with diversities from 
106 to 1010. This technology is of particular interest to study protein interactions and offers 
many advantages: (i) the peptides, proteins, or protein fragments expressed at the surface of 
phages particles are solvent-exposed and thus accessible for interaction with their targets; (ii) 
the bacteriophage can easily be purified; and (iii) there is a physical link between the 
phenotype and the corresponding genotype. However, phage display presents a few 
bottlenecks: (i) the lack of an easy and rapid quality control of the representativeness of the 
initial library; (ii) the lack of a direct assessment of the enrichment level of libraries during 
the successive rounds of panning without interfering with the phage elution step and finally 
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(iii) the large nucleotidic sequencing efforts necessary to characterize the selected epitope. 
This can be time-consuming and laborious.  
To overcome these difficulties, Legendre and co-workers proposed to combine the phage 
display technology with the enzymatic activity of the E.coli TEM-1 β-lactamase. They 
identified two loops near the active site of the enzyme in which small peptides could be 
inserted, replacing one or two codons of the TEM-1 gene [73]. They displayed libraries of 
hybrid β-lactamases on the surface of phages and selected them for affinity towards specific 
targets. Allosteric regulations (inhibition or activation) of the enzyme activity were observed 
for some hybrid proteins upon interaction with their specific targets [46]. This coupling 
between the phage display technology and the enzymatic β-lactamase activity presents 
several advantages: (i) it decreases the conformational freedom of the displayed inserted 
protein fragment; (ii) it protects the inserted polypeptide from proteolytic cleavage; (iii) it 
allows to directly assess the interaction of the inserted fragments using the β-lactamase as a 
reporter activity; (iv) the enzymatic activity can also be used to monitor the enrichment of the 
libraries during the successive selection rounds; and finally (v) it facilitates the determination 
of the best parameters of the assay as well as the optimization of the experimental procedure. 
Recently Filée and co-workers have implemented this coupling between phage display and 
the so-called “bifunctional hybrid β-lactamase technology” (BHP) to perform epitope 
mapping. Furthermore, they validated the use of these combined technologies to methods 





In immunology, epitope mapping is used to study antigen/antibody (B-cell epitope) or 
antigen/T cell receptor (T cell epitope) interactions, develop immunoassays, identify 
neutralising sites, produce protective peptide vaccines, develop hypoallergens, investigate the 
pathogenesis of autoimmune diseases, etc. Chevigné and co-workers demonstrated that using 
the hybrid β-lactamase technology coupled with phage display could not only identify protein 
regions involved in protein-protein interactions but also supply useful molecules in which 
these regions are linked to an enzymatic activity [74]. They validated this approach by 
preparing an influenza virus hemagglutinin (HA1) gene fragment library inserted into the 
solvent-exposed permissive loop of the Bacillus licheniformis BlaP β-lactamase (position 
198). Hybrid β-lactamases, fused to protein pIII of the fdTet phage, were exposed on the 
surface of phage particles. This library was successfully used to select a linear epitope 
recognised by a monoclonal antibody. The procedure alternating successive affinity selection 
of phages and growth of phage infected cells in the presence of β-lactams allows the selection 
of bifunctional hybrid β-lactamases with high affinity for the target ligand (figure 10). 
Furthermore they demonstrated that modifying the β-lactam concentration in the culture 
medium results in a positive selection of hybrid β-lactamases that retain a native-like catalytic 
efficiency. This is a useful tool to accelerate the convergent selection of bifunctional β-
lactamases.  
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Figure 10. Schematic representation of the epitope mapping procedure [74].  
 
Biosensor 
As mentioned above, since the hydrolysis of β-lactams generates protons, β-lactamases 
are good candidates for the development of enzyme-based biosensors. Recently, Ruth and co-
workers combined the phage display-BHP technology with potentiometric biosensor and 
validated this system for the epitope mapping of the human epidermal growth factor receptor 
(hegfr) (submitted publication). The hegfr cDNA was randomly digested and used to generate 
a random epitope library within the BlaP β-lactamase. This library, exposed on the surface of 
the fdTet phage, was screened by affinity selection against mouse monoclonal anti-human 
EGFr using phage display. The biopanning was successfully achieved by coating the anti-
EGFr antibodies on a biosensor platform composed of a carbon electrode coated with a thin 
layer of polyalanine (PANI) (Figure 11). They demonstrated that the release of protons during 
benzylpenicillin hydrolysis induces a detectable change of electrode potential between the 
PANI-coated carbon and calomel reference electrodes upon specific binding of various 
monoclonal antibodies to phages harbouring the antibodies related epitopes. This indicated 
that biofunctionnalized PANI-electrode constitutes a suitable platform for performing 
biological screening with the advantage that this type of measurement is less time consuming 
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Figure 11. Schematic representation of the epitope mapping procedure combining the combinatorial 
search for target domains based on hybrid protein synthesis, Phage display, Potentiometric biosensor 
and DNA-array. SCE: saturated calomel electrode. ΔU: electrical potential variation. A: PCR 
amplification of the gene coding for the target protein (cDNA encoding the hEGFR) and random 
digestion of the PCR product with DNaseI. B: cloning of the gene fragments into the fdTet BlaP 
phagemide. A positive selection is performed to select infectious and β-lactamase positive phages. C: 
amplification of phage particles in E. coli. D: DNA-array analysis to verify the representativeness of the 
initial library. E: Capture of the phages with specific antibodies (mab H11). F: washing step. G: 
measurement of the immobilized β-lactamase activity on the potentiometric biosensor using 
benzylpenicillin as substrate. H: Elution step. I: amplification of eluted phages particles in E. coli and 
performance of a new round of biopanning. J: DNA-array analysis to identify the mAb H11 epitope. K: 




The DNA-array technology is used for expression profiling, to monitor expression levels 
of thousands of genes simultaneously, for comparative genomic hybridization, for 
identification of protein binding sites or for the identification of single nucleotide 
polymorphism in the genome of populations. The nucleotidic material spotted on microarrays 
can be oligonucleotides, cDNA or PCR products. Consequently the broad diversity of 
nucleotidic material that can be used offers many possibilities of detection in various 
biological contexts [75-76]. Ruth and co-workers took advantage of the phage-display-BHP 
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technology to develop a new generation of DNA-array (Figure 11). Indeed, in addition to the 
complementation of the β-lactamase based potentiometric biosensor used to map epitope of 
the human epidermal growth factor receptor (hegfr), they constructed a so called “epitope 
array” also based on the combination of phage-display-BHP technologies. In practice, the 
“epitope-array” was created by spotting short adjacent oligonucleotides covering the coding 
sequence of hEGFR. Labelled probes were prepared from hegfr gene fragments cloned into 
the BlaP gene by PCR amplification incorporating dCTP-cy5 or cy-3. By combining the array 
results obtained with both the non-coding and coding strands of hegfr, they concluded that the 
different hEGFR protein regions displayed on phages from the initial library entirely covered 
the protein sequence and gave rise to β-lactamase positive and infectious phages. Moreover, 
the array experiments performed with phages obtained after two rounds of screening 
confirmed that fluorescence signals were only observed with oligonucleotides that encoded a 
protein region which overlapped that mapped with the multiple sequence alignment. Taking 
advantage of fluorescence intensities obtained on each spotted oligonucleotide, they reduced 
the epitope to a 28 residues polypeptide. Altogether, this indicates that the implementation of 
the phage display-BHP technology into DNA array presents the advantage to control the 
quality of the initial library and can be successfully used to identify the nucleotide sequence 
that encodes the polypeptide selected during the phage display procedure.  
 
 
7. THE USE OF β-LACTAMASE IN DNA/PROTEIN VACCINATION 
 
Another interesting application field of β-lactamases is their use as hapten-carrier 
proteins to develop vaccines against non-immunogenic proteins. A good example is the work 
described by Ruth and co-workers who developed a DNA vaccination system against the 
heat-stable enterotoxin STa from Escherichia coli [77]. This toxin is a major cause of enteric 
colibacillosis, characterized by profuse fluid diarrhoea leading to dehydration and even death 
of newborn calves and piglets [78-79]. Because of its small size, STa is poorly antigenic and 
not immunogenic in its native form. Several approaches were explored to obtain non-toxic 
immunogenic molecules for safe vaccine design. Several proteins were chemically coupled to 
STa in order to increase the immunogenicity of the enterotoxin, including bovine serum 
albumin [80], the B-subunit of cholera toxin (CTB) [81] and the heat-labile enterotoxin [81-
82]. Some hybrid fusion proteins were constructed between STa and the major subunit ClpG 
of the E.coli surface antigen (ClpG-ST) [83], between STa and one or more subunits of the 
cholera toxin [84-85] and between STa and LT (labile toxin) [86-87]. The OmpC outer-
membrane protein and the flagellin have also been used as carriers for STa [88-89]. However, 
in general, these constructions failed to elicit the production of neutralizing antibodies or 
retained some degree of STa-associated toxicity, probably because the immunogenic 
properties of the toxin are influenced by the conformation associated with toxicity. In 
consequence, Ruth and co-workers decided to insert the STa toxin in the solvent-exposed 
permissive loop (position 195) of the E.coli TEM-1 β-lactamase in order to enhance its 
immunogenic properties. Furthermore, since the production and purification of hybrid protein 
vaccines is labour intensive and expensive, they choose to validate this system using the DNA 
vaccine technology. Indeed, DNA vaccines are stable, easy to produce, and potent tools for 
inducing both humoral and cell-mediated immune responses [90-91]. Moreover, immune 
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responses induced by DNA vaccines may display a broader epitopic repertoire than immune 
responses induced by traditional peptide or protein vaccines [92-93]. In this context, Ruth et 
al genetically inserted the nucleotide sequence of STa into the TEM-1 gene and cloned the 
constructed hybrid gene into an appropriate plasmid DNA expression vector (V1Jns.tPA 
vector). The plasmids were tested for their capacity to induce a TEM-1 and STa specific 
immune response in a mice model. No STa specific IgG could be detected after three DNA 
immunizations. But a boost with the oligopeptide toxin, which is not immunogenic in its 
native form, induced high STa specific antibody titres. This demonstrated that immunization 
with plasmid DNA encoding hybrid hapten-carrier proteins, in this case a β-lactamase with 
the E.coli STa insert, can be used as a priming stimulus to provide an antibody response 
against a non-immunogenic peptide.  
 
 
Figure 12. Schematic representation of the antibody-directed enzyme prodrug therapy (ADEPT) in 
which enzymes are localized to the surface of the target cell where they activate systemically 
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8. β-LACTAMASES AS AN ANTIBODY DIRECTED ENZYME 
 IN PRODRUG THERAPY  
 
The toxicities associated with conventional cancer chemotherapy arise primarily from the 
lack of specificity for tumour cells [94]. Most of the presently available drugs are designed to 
be selectively toxic for rapidly dividing cells [95]. A variety of approaches are under 
development to improve the efficency and tumor cell specificity of cancer treatments. Many 
of these involve monoclonal antibodies and offer attractive means of directing toxic agents 
such as drugs, radioisotopes, protein cytotoxins, cytokines, effector cells of the immune 
system and enzymes to tumor cells. In one approach, known as antibody-directed enzyme 
prodrug therapy (ADEPT) (Figure 12), enzymes are delivered to tumor cells via the 
recognition of tumor associated antigens (by a specific antibody conjugated to the enzyme) 
where they catalyse the activation of a pro-drug exactly at the site of tumor [94].  
This method is now well advanced, with many examples of systems already tested in 
preclinical models and some entering clinical trials. Enzymes usually utilized in ADEPT 
include alkaline phosphatase, carboxypeptidases, β-glucosidases and β-lactamases. Many β-
lactamases hydrolyse a wide range of cephalosporins with 3’ leaving groups which are 
released upon hydrolysis of the β-lactam ring. Various toxic compounds can thus be released 
from cephalosporin prodrugs, including nitrogen mustard and vinca alkaloid derivatives [96]. 
Moreover, eukaryotic cells do not produce β-lactamases related enzymes which could cause 
unwanted activation of prodrugs in vivo. A cocktail of different prodrugs can be activated by 
β-lactamases to release a panel of active drugs which can act independently or synergistically. 
These reasons explain why β-lactamases are good candidates for this particular application, 
and examples of their in vitro utilization, with the L6 monoclonal antibody, have 
demonstrated good targeted prodrug activation [97]. The prodrug tested was cephalosporin 
mustard (CM) which was designed as an anticancer prodrug that can be activated by a site-
specific L6 monoclonal antibody-β-lactamase conjugates targeted to antigens present on 
tumour cell surfaces. The antibody-β-lactamase conjugate catalyzes the release of the active 
drug phenyl mustard (PDM). Similar antibodies - β - lactamase conjugates have also been 
assayed with different prodrugs [98]. More recently, Roberge and co-workers described the 
construction of a novel antibody-enzyme fusion protein for use in ADEPT [99]. The fusion 
protein combines the proven tumour specificity of the CC49 antibody [100] with β-lactamase. 
But this first generation of fusion proteins is rapidly degraded when expressed in E.coli. 
Optimization of the antibody fragment by combinatorial consensus mutagenesis (CCM), 
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